{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:45:35Z","timestamp":1757706335611},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.4065\/82.3.351","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:29:19Z","timestamp":1232760559000},"page":"351-355","source":"Crossref","is-referenced-by-count":5,"title":["Nonsurgical Management of Primary Hyperparathyroidism"],"prefix":"10.4065","volume":"82","author":[{"given":"Bryan","family":"Farford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. John","family":"Presutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Moraghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/82.3.351_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/77.1.87","article-title":"Medical and surgical management of hyperparathyroidism [published correction appears in Mayo Clin Proc. 2002;77:298]","volume":"77","author":"Kearns","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/82.3.351_bib2","first-page":"333","article-title":"Hyperparathyroidism","volume":"69","author":"Taniegra","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.4065\/82.3.351_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.7326\/0003-4819-126-6-199703150-00003","article-title":"The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992","volume":"126","author":"Wermers","year":"1997","journal-title":"Ann Intern Med"},{"issue":"suppl 2","key":"10.4065\/82.3.351_bib4","first-page":"N2","article-title":"Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century","volume":"17","author":"Bilezikian","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.4065\/82.3.351_bib5","unstructured":"Fuleihan Gel-H. Clinical manifestations of primary hyperparathyroidism. In: Rose BD, ed. UpToDate Waltham, Ma; 2005."},{"key":"10.4065\/82.3.351_bib6","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMcp032200","article-title":"Clinical practice: asymptomatic primary hyperparathyroidism","volume":"350","author":"Bilezikian","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.351_bib7","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/82.3.351_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/82.3.351_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199910213411709","article-title":"Treatment of primary hyperparathyroidism","volume":"341","author":"Utiger","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.351_bib10","unstructured":"Agus ZS. Management of asymptomatic primary hyperparathyroidism. In: Rose BD. ed. UpToDate. Waltham, Ma; 2005."},{"key":"10.4065\/82.3.351_bib11","unstructured":"Agus ZS, Savarese DMF, Berenson JR. Treatment of hypercalcemia. In: Rose BD. ed. UpToDate. Waltham, Ma; 2005."},{"key":"10.4065\/82.3.351_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery [published correction appears in N Engl J Med. 2000;342:144]","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.351_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/82.3.351_bib14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1210\/jc.77.4.1067","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate","volume":"77","author":"Reasner","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/82.3.351_bib15","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/82.3.351_bib16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.351_bib17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.351_bib18","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/82.3.351_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1359\/jbmr.2001.16.1.189","article-title":"Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism","volume":"16","author":"Zanchetta","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.4065\/82.3.351_bib22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/82.3.351_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1530\/eje.0.1360240","article-title":"Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases","volume":"136","author":"Bennedbaek","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"10.4065\/82.3.351_bib24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1067\/msy.1998.91826","article-title":"Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism","volume":"124","author":"Harman","year":"1998","journal-title":"Surgery"},{"key":"10.4065\/82.3.351_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2265.1993.tb00349.x","article-title":"Ultrasonically guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a follow-up study","volume":"38","author":"Karstrup","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/82.3.351_bib26","series-title":"Basic and Clinical Pharmacology","first-page":"251","article-title":"Diuretic agents","author":"Ives","year":"1998"},{"key":"10.4065\/82.3.351_bib27","first-page":"2256","article-title":"Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders","volume":"Vol 2","author":"Potts","year":"2005"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611610318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611610318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T07:55:35Z","timestamp":1545465335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611610318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0025619611610318"],"URL":"https:\/\/doi.org\/10.4065\/82.3.351","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}